{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:44:01Z","timestamp":1788371041536,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:00:00Z","timestamp":1691971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:00:00Z","timestamp":1691971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002283","name":"Alzheimer\u2019s Research UK","doi-asserted-by":"publisher","award":["ARUK-SRF2018-001"],"award-info":[{"award-number":["ARUK-SRF2018-001"]}],"id":[{"id":"10.13039\/501100002283","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017510","name":"UK Dementia Research Institute","doi-asserted-by":"publisher","award":["UKDRI-1014"],"award-info":[{"award-number":["UKDRI-1014"]}],"id":[{"id":"10.13039\/501100017510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000833","name":"Rosetrees Trust","doi-asserted-by":"publisher","award":["MB2020\\100003"],"award-info":[{"award-number":["MB2020\\100003"]}],"id":[{"id":"10.13039\/501100000833","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["098330\/Z\/12\/Z"],"award-info":[{"award-number":["098330\/Z\/12\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["098328"],"award-info":[{"award-number":["098328"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["098327"],"award-info":[{"award-number":["098327"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["CHEMCHECK (679921)"],"award-info":[{"award-number":["CHEMCHECK (679921)"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cathepsin B is a cysteine protease that is implicated in multiple aspects of Alzheimer\u2019s disease pathogenesis. The endogenous inhibitor of this enzyme, cystatin B (\n                    <jats:italic>CSTB)<\/jats:italic>\n                    is encoded on chromosome 21. Thus, individuals who have Down syndrome, a genetic condition caused by having an additional copy of chromosome 21, have an extra copy of an endogenous inhibitor of the enzyme. Individuals who have Down syndrome are also at significantly increased risk of developing early-onset Alzheimer\u2019s disease (EOAD). The impact of the additional copy of\n                    <jats:italic>CSTB<\/jats:italic>\n                    on Alzheimer\u2019s disease development in people who have Down syndrome is not well understood. Here we compared the biology of cathepsin B and CSTB in individuals who had Down syndrome and Alzheimer\u2019s disease, with disomic individuals who had Alzheimer\u2019s disease or were ageing healthily. We find that the activity of cathepsin B enzyme is decreased in the brain of people who had Down syndrome and Alzheimer\u2019s disease compared with disomic individuals who had Alzheimer\u2019s disease. This change occurs independently of an alteration in the abundance of the mature enzyme or the number of cathepsin B\n                    <jats:sup>+<\/jats:sup>\n                    cells. We find that the abundance of CSTB is significantly increased in the brains of individuals who have Down syndrome and Alzheimer\u2019s disease compared to disomic individuals both with and without Alzheimer\u2019s disease. In mouse and human cellular preclinical models of Down syndrome, three-copies of\n                    <jats:italic>CSTB<\/jats:italic>\n                    increases CSTB protein abundance but this is not sufficient to modulate cathepsin B activity. EOAD and Alzheimer\u2019s disease-Down syndrome share many overlapping mechanisms but differences in disease occur in individuals who have trisomy 21. Understanding this biology will ensure that people who have Down syndrome access the most appropriate Alzheimer\u2019s disease therapeutics and moreover will provide unique insight into disease pathogenesis more broadly.\n                  <\/jats:p>","DOI":"10.1186\/s40478-023-01632-8","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T16:04:23Z","timestamp":1692029063000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Cathepsin B abundance, activity and microglial localisation in Alzheimer\u2019s disease-Down syndrome and early onset Alzheimer\u2019s disease; the role of elevated cystatin B"],"prefix":"10.1186","volume":"11","author":[{"given":"Yixing","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Mumford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanna","family":"Noy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Cleverley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Mrzyglod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinghao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris","family":"van Dalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Verdoes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M. C.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9323-3548","authenticated-orcid":false,"given":"Frances K.","family":"Wiseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,14]]},"reference":[{"issue":"11","key":"1632_CR1","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S1474-4422(21)00245-3","volume":"20","author":"J Fortea","year":"2021","unstructured":"Fortea J et al (2021) Alzheimer\u2019s disease associated with Down syndrome: a genetic form of dementia. Lancet Neurol 20(11):930\u2013942","journal-title":"Lancet Neurol"},{"issue":"1","key":"1632_CR2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ng1718","volume":"38","author":"A Rovelet-Lecrux","year":"2006","unstructured":"Rovelet-Lecrux A et al (2006) APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38(1):24\u201326","journal-title":"Nat Genet"},{"issue":"6","key":"1632_CR3","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/alz.12463","volume":"18","author":"M Sawa","year":"2022","unstructured":"Sawa M et al (2022) Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model. Alzheimers Dement 18(6):1203\u20131234","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1632_CR4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3233\/JAD-160836","volume":"56","author":"E Doran","year":"2017","unstructured":"Doran E et al (2017) Down syndrome, partial trisomy 21, and absence of Alzheimer\u2019s disease: the role of APP. J Alzheimers Dis 56(2):459\u2013470","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"1632_CR5","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/ana.410430316","volume":"43","author":"VP Prasher","year":"1998","unstructured":"Prasher VP et al (1998) Molecular mapping of Alzheimer-type dementia in Down\u2019s syndrome. Ann Neurol 43(3):380\u2013383","journal-title":"Ann Neurol"},{"key":"1632_CR6","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.1038\/s41380-020-0806-5","volume":"26","author":"I Alic","year":"2021","unstructured":"Alic I et al (2021) Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. Mol Psychiatry 26:5766\u20135788","journal-title":"Mol Psychiatry"},{"key":"1632_CR7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.nbd.2017.06.010","volume":"106","author":"S Garcia-Cerro","year":"2017","unstructured":"Garcia-Cerro S et al (2017) Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer\u2019s disease phenotypes. Neurobiol Dis 106:76\u201388","journal-title":"Neurobiol Dis"},{"issue":"33","key":"1632_CR8","doi-asserted-by":"crossref","first-page":"6453","DOI":"10.1523\/JNEUROSCI.0521-22.2022","volume":"42","author":"P Mumford","year":"2022","unstructured":"Mumford P et al (2022) Genetic mapping of APP and amyloid-beta biology modulation by trisomy 21. J Neurosci 42(33):6453\u20136468","journal-title":"J Neurosci"},{"issue":"1","key":"1632_CR9","doi-asserted-by":"crossref","first-page":"5736","DOI":"10.1038\/s41598-021-85062-3","volume":"11","author":"JL Tosh","year":"2021","unstructured":"Tosh JL et al (2021) Genetic dissection of down syndrome-associated alterations in APP\/amyloid-beta biology using mouse models. Sci Rep 11(1):5736","journal-title":"Sci Rep"},{"issue":"8","key":"1632_CR10","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1093\/brain\/awy159","volume":"141","author":"FK Wiseman","year":"2018","unstructured":"Wiseman FK et al (2018) Trisomy of human chromosome 21 enhances amyloid-beta deposition independently of an extra copy of APP. Brain 141(8):2457\u20132474","journal-title":"Brain"},{"issue":"5","key":"1632_CR11","doi-asserted-by":"crossref","DOI":"10.1172\/JCI152170","volume":"132","author":"Q Zheng","year":"2022","unstructured":"Zheng Q et al (2022) USP25 inhibition ameliorates Alzheimer\u2019s pathology through the regulation of APP processing and Abeta generation. J Clin Invest 132(5):e152170","journal-title":"J Clin Invest"},{"issue":"12","key":"1632_CR12","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1093\/brain\/awaa326","volume":"143","author":"L Flores-Aguilar","year":"2020","unstructured":"Flores-Aguilar L et al (2020) Evolution of neuroinflammation across the lifespan of individuals with Down syndrome. Brain 143(12):3653\u20133671","journal-title":"Brain"},{"issue":"1","key":"1632_CR13","volume":"12","author":"AC Martini","year":"2020","unstructured":"Martini AC et al (2020) Distribution of microglial phenotypes as a function of age and Alzheimer\u2019s disease neuropathology in the brains of people with Down syndrome. Alzheimers Dement (Amst) 12(1):e12113","journal-title":"Alzheimers Dement (Amst)"},{"issue":"47","key":"1632_CR14","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2114326118","volume":"118","author":"CR Palmer","year":"2021","unstructured":"Palmer CR et al (2021) Altered cell and RNA isoform diversity in aging Down syndrome brains. Proc Natl Acad Sci USA 118(47):e2114326118","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"1632_CR15","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1016\/j.neurobiolaging.2015.05.016","volume":"36","author":"DM Wilcock","year":"2015","unstructured":"Wilcock DM et al (2015) Down syndrome individuals with Alzheimer\u2019s disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer\u2019s disease. Neurobiol Aging 36(9):2468\u20132474","journal-title":"Neurobiol Aging"},{"key":"1632_CR16","doi-asserted-by":"crossref","unstructured":"Zheng Q et al (2021) Trisomy 21-induced dysregulation of microglial homeostasis in Alzheimer's brains is mediated by USP25. Sci Adv 7(1):eabe1340.","DOI":"10.1126\/sciadv.abe1340"},{"issue":"4","key":"1632_CR17","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41588-022-01024-z","volume":"54","author":"C Bellenguez","year":"2022","unstructured":"Bellenguez C et al (2022) New insights into the genetic etiology of Alzheimer\u2019s disease and related dementias. Nat Genet 54(4):412\u2013436","journal-title":"Nat Genet"},{"key":"1632_CR18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.arr.2016.04.010","volume":"32","author":"V Stoka","year":"2016","unstructured":"Stoka V, Turk V, Turk B (2016) Lysosomal cathepsins and their regulation in aging and neurodegeneration. Ageing Res Rev 32:22\u201337","journal-title":"Ageing Res Rev"},{"issue":"1","key":"1632_CR19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3233\/JAD-221005","volume":"93","author":"G Hook","year":"2023","unstructured":"Hook G, Kindy M, Hook V (2023) Cathepsin B deficiency improves memory deficits and reduces amyloid-\u03b2 in hA\u03b2PP mouse models representing the major sporadic Alzheimer\u2019s disease condition. J Alzheimers Dis 93(1):33\u201346","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"1632_CR20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.neuron.2008.10.001","volume":"60","author":"B Sun","year":"2008","unstructured":"Sun B et al (2008) Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer\u2019s disease. Neuron 60(2):247\u2013257","journal-title":"Neuron"},{"issue":"8","key":"1632_CR21","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbapap.2020.140428","volume":"1868","author":"V Hook","year":"2020","unstructured":"Hook V et al (2020) Cathepsin B in neurodegeneration of Alzheimer\u2019s disease, traumatic brain injury, and related brain disorders. Biochim Biophys Acta Proteins Proteom 1868(8):140428","journal-title":"Biochim Biophys Acta Proteins Proteom"},{"issue":"2","key":"1632_CR22","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/bpa.12483","volume":"27","author":"MT Heneka","year":"2017","unstructured":"Heneka MT (2017) Inflammasome activation and innate immunity in Alzheimer\u2019s disease. Brain Pathol 27(2):220\u2013222","journal-title":"Brain Pathol"},{"issue":"27","key":"1632_CR23","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1523\/JNEUROSCI.0578-19.2019","volume":"39","author":"Y Jiang","year":"2019","unstructured":"Jiang Y et al (2019) Lysosomal dysfunction in down syndrome is APP-dependent and mediated by APP-\u03b2CTF (C99). J Neurosci 39(27):5255\u20135268","journal-title":"J Neurosci"},{"issue":"1","key":"1632_CR24","first-page":"10","volume":"2","author":"CN Suire","year":"2021","unstructured":"Suire CN, Leissring MA (2021) Cathepsin D: a candidate link between amyloid \u03b2-protein and tauopathy in Alzheimer disease. J Exp Neurol 2(1):10\u201315","journal-title":"J Exp Neurol"},{"issue":"3","key":"1632_CR25","doi-asserted-by":"crossref","first-page":"G548","DOI":"10.1152\/ajpgi.00047.2016","volume":"311","author":"LE Edgington-Mitchell","year":"2016","unstructured":"Edgington-Mitchell LE et al (2016) Legumain is activated in macrophages during pancreatitis. Am J Physiol-Gastrointest Liver Physiol 311(3):G548\u2013G560","journal-title":"Am J Physiol-Gastrointest Liver Physiol"},{"issue":"4","key":"1632_CR26","doi-asserted-by":"crossref","first-page":"C723","DOI":"10.1152\/ajpcell.00462.2010","volume":"300","author":"KW Dunn","year":"2011","unstructured":"Dunn KW, Kamocka MM, McDonald JH (2011) A practical guide to evaluating colocalization in biological microscopy. Am J Physiol Cell Physiol 300(4):C723\u2013C742","journal-title":"Am J Physiol Cell Physiol"},{"issue":"4","key":"1632_CR27","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","volume":"112","author":"H Braak","year":"2006","unstructured":"Braak H et al (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112(4):389\u2013404","journal-title":"Acta Neuropathol"},{"issue":"1","key":"1632_CR28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/exnr.1994.1048","volume":"126","author":"H Nakanishi","year":"1994","unstructured":"Nakanishi H et al (1994) Age-related changes in activities and localizations of cathepsins D, E, B, and L in the rat brain tissues. Exp Neurol 126(1):119\u2013128","journal-title":"Exp Neurol"},{"issue":"5","key":"1632_CR29","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.neuron.2020.09.010","volume":"108","author":"B Pinto","year":"2020","unstructured":"Pinto B et al (2020) Rescuing over-activated microglia restores cognitive performance in juvenile animals of the Dp(16) mouse model of down syndrome. Neuron 108(5):887-904.e12","journal-title":"Neuron"},{"issue":"39","key":"1632_CR30","doi-asserted-by":"crossref","first-page":"14726","DOI":"10.1021\/ja4056068","volume":"135","author":"M Verdoes","year":"2013","unstructured":"Verdoes M et al (2013) Improved quenched fluorescent probe for imaging of cysteine cathepsin activity. J Am Chem Soc 135(39):14726\u201314730","journal-title":"J Am Chem Soc"},{"issue":"Pt 1","key":"1632_CR31","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/brain\/awq341","volume":"134","author":"DS Yang","year":"2011","unstructured":"Yang DS et al (2011) Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer\u2019s disease ameliorates amyloid pathologies and memory deficits. Brain 134(Pt 1):258\u2013277","journal-title":"Brain"},{"issue":"2","key":"1632_CR32","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/sj.ejhg.5201300","volume":"13","author":"K Alakurtti","year":"2005","unstructured":"Alakurtti K et al (2005) Loss of lysosomal association of cystatin B proteins representing progressive myoclonus epilepsy, EPM1, mutations. Eur J Hum Genet 13(2):208\u2013215","journal-title":"Eur J Hum Genet"},{"issue":"5","key":"1632_CR33","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nn.3697","volume":"17","author":"T Saito","year":"2014","unstructured":"Saito T et al (2014) Single App knock-in mouse models of Alzheimer\u2019s disease. Nat Neurosci 17(5):661\u2013663","journal-title":"Nat Neurosci"},{"issue":"7","key":"1632_CR34","volume":"16","author":"Y Wu","year":"2021","unstructured":"Wu Y et al (2021) The effects of Cstb duplication on APP\/amyloid-beta pathology and cathepsin B activity in a mouse model. PLoS ONE 16(7):e0242236","journal-title":"PLoS ONE"},{"key":"1632_CR35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fcell.2020.00167","volume":"8","author":"A Chevriaux","year":"2020","unstructured":"Chevriaux A et al (2020) Cathepsin B is required for NLRP3 inflammasome activation in macrophages, through NLRP3 interaction. Front Cell Dev Biol 8:167","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"1632_CR36","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s11481-016-9721-6","volume":"12","author":"CM Embury","year":"2017","unstructured":"Embury CM et al (2017) Cathepsin B improves \u00df-amyloidosis and learning and memory in models of Alzheimer\u2019s disease. J Neuroimmune Pharmacol 12(2):340\u2013352","journal-title":"J Neuroimmune Pharmacol"},{"key":"1632_CR37","volume":"13","author":"TJ Oberstein","year":"2020","unstructured":"Oberstein TJ et al (2020) The role of cathepsin B in the degradation of A\u03b2 and in the production of A\u03b2 peptides starting with Ala2 in cultured astrocytes. Front Mol Neurosci 13:615740","journal-title":"Front Mol Neurosci"},{"issue":"10","key":"1632_CR38","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1073\/pnas.87.10.3861","volume":"87","author":"AM Cataldo","year":"1990","unstructured":"Cataldo AM, Nixon RA (1990) Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain. Proc Natl Acad Sci USA 87(10):3861\u20133865","journal-title":"Proc Natl Acad Sci USA"},{"issue":"24","key":"1632_CR39","doi-asserted-by":"crossref","first-page":"10998","DOI":"10.1073\/pnas.88.24.10998","volume":"88","author":"AM Cataldo","year":"1991","unstructured":"Cataldo AM et al (1991) Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer disease. Proc Natl Acad Sci USA 88(24):10998\u201311002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"1632_CR40","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3233\/JAD-2010-101023","volume":"22","author":"J Sundel\u00f6f","year":"2010","unstructured":"Sundel\u00f6f J et al (2010) Higher cathepsin B levels in plasma in Alzheimer\u2019s disease compared to healthy controls. J Alzheimers Dis 22(4):1223\u20131230","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"1632_CR41","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.3390\/ijms18081806","volume":"18","author":"F Morena","year":"2017","unstructured":"Morena F et al (2017) A comparison of lysosomal enzymes expression levels in peripheral blood of mild- and severe-Alzheimer\u2019s disease and MCI patients: implications for regenerative medicine approaches. Int J Mol Sci 18(8):1806","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1632_CR42","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.neurobiolaging.2013.08.003","volume":"35","author":"R Tiribuzi","year":"2014","unstructured":"Tiribuzi R et al (2014) miR128 up-regulation correlates with impaired amyloid \u03b2(1\u201342) degradation in monocytes from patients with sporadic Alzheimer\u2019s disease. Neurobiol Aging 35(2):345\u2013356","journal-title":"Neurobiol Aging"},{"issue":"10242","key":"1632_CR43","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/S0140-6736(20)30689-9","volume":"395","author":"J Fortea","year":"2020","unstructured":"Fortea J et al (2020) Clinical and biomarker changes of Alzheimer\u2019s disease in adults with Down syndrome: a cross-sectional study. Lancet 395(10242):1988\u20131997","journal-title":"Lancet"},{"issue":"1","key":"1632_CR44","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3233\/JAD-142805","volume":"45","author":"Y Sun","year":"2015","unstructured":"Sun Y et al (2015) Translational study of Alzheimer\u2019s disease (AD) biomarkers from brain tissues in A\u03b2PP\/PS1 mice and serum of AD patients. J Alzheimers Dis 45(1):269\u2013282","journal-title":"J Alzheimers Dis"},{"key":"1632_CR45","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3389\/fnmol.2019.00195","volume":"12","author":"E Penna","year":"2019","unstructured":"Penna E et al (2019) Cystatin B involvement in synapse physiology of rodent brains and human cerebral organoids. Front Mol Neurosci 12:195","journal-title":"Front Mol Neurosci"},{"key":"1632_CR46","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3389\/fncel.2015.00458","volume":"9","author":"N Kopitar-Jerala","year":"2015","unstructured":"Kopitar-Jerala N (2015) The role of Stefin B in neuro-inflammation. Front Cell Neurosci 9:458","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"1632_CR47","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ana.25752","volume":"88","author":"ME Curtis","year":"2020","unstructured":"Curtis ME, Yu D, Pratico D (2020) Dysregulation of the retromer complex system in down syndrome. Ann Neurol 88(1):137\u2013147","journal-title":"Ann Neurol"},{"issue":"8","key":"1632_CR48","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.bbadis.2013.04.013","volume":"1832","author":"F Di Domenico","year":"2013","unstructured":"Di Domenico F et al (2013) Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer\u2019s disease neuropathology: redox proteomics analysis of human brain. Biochim Biophys Acta 1832(8):1249\u20131259","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"1632_CR49","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bpa.12631","volume":"29","author":"YL Chai","year":"2019","unstructured":"Chai YL et al (2019) Lysosomal cathepsin D is upregulated in Alzheimer\u2019s disease neocortex and may be a marker for neurofibrillary degeneration. Brain Pathol 29(1):63\u201374","journal-title":"Brain Pathol"},{"issue":"12","key":"1632_CR50","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1080\/15548627.2016.1239003","volume":"12","author":"M Bordi","year":"2016","unstructured":"Bordi M et al (2016) Autophagy flux in CA1 neurons of Alzheimer hippocampus: Increased induction overburdens failing lysosomes to propel neuritic dystrophy. Autophagy 12(12):2467\u20132483","journal-title":"Autophagy"},{"issue":"3","key":"1632_CR51","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/0896-6273(95)90324-0","volume":"14","author":"AM Cataldo","year":"1995","unstructured":"Cataldo AM et al (1995) Gene expression and cellular content of cathepsin D in Alzheimer\u2019s disease brain: evidence for early up-regulation of the endosomal-lysosomal system. Neuron 14(3):671\u2013680","journal-title":"Neuron"},{"issue":"1","key":"1632_CR52","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-020-00649-8","volume":"12","author":"CN Suire","year":"2020","unstructured":"Suire CN et al (2020) Cathepsin D regulates cerebral A\u03b242\/40 ratios via differential degradation of A\u03b242 and A\u03b240. Alzheimers Res Ther 12(1):80","journal-title":"Alzheimers Res Ther"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-023-01632-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-023-01632-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-023-01632-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T10:47:57Z","timestamp":1700218077000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-023-01632-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,14]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1632"],"URL":"https:\/\/doi.org\/10.1186\/s40478-023-01632-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.06.20.545700","asserted-by":"object"}]},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,14]]},"assertion":[{"value":"20 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"<i>Human tissue<\/i> The procurement and use of human tissues in this study was in accordance with the UK Human Tissue Act 2004. The study was reviewed and approved by NHS Research Ethics committee, London-Queen Square (REC 09\/H0716\/57). All samples were supplied, anonymized by the South West Dementia Brain Bank, Bristol University, UK, and had full research consent (REC 18\/SW\/0029). <i>Animal research<\/i> All experiments were undertaken in accordance with the Animals (Scientific Procedures) Act 1986 (United Kingdom), after local institutional ethical review by the Medical Research Council, University College London under licence from the UK government and reported in accordance with ARRIVE 2.0 guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}